Ipca Labs Q1 FY27: Profit Up 72%, Guidance Raised

Ipca Laboratories Limited reported Q1 FY27 results for the June 2026 quarter on 13 August. Q1 FY27 numbers (consolidated): Revenue: Rs 2,788 crore, up 21% YoY; 7.7% above consensus EBITDA: Rs 638 crore, up 50% YoY; margin 22.88% vs 18.39% PAT: Rs 401.9 crore, up 72% YoY; EPS Rs 15.84 vs Rs 12.43 expected Domestic formulations up 13%; exports Rs 603 crore, up 34%, Europe up 70%; API up 30% Guidance raised: FY27 revenue growth to 14 to 16% from 12 to 13%, EBITDA margin to about 23% from 22%, with 25 to 26% targeted medium term. Two footnotes: institutional exports doubled partly on Rs 40 crore deferred from March, and the weak rupee was a net margin positive. JM Financial, Nuvama and Prabhudas Lilladher hold Buy, targets Rs 2,000 to 2,118. Ipca Labs [][***** shares closed at Rs 1,942.99 on the linked page on 3 September 2026, up 12 percent since results, 39 percent in a year, after a record Rs 2,001.50 in recent sessions. P/E 37.6; PEG 0.7. My view: a deserved re-rating that the market completed before you could act on it. The beat is broad and the guidance raise credible, with Unichem's drag fading and API and Europe running; strip the deferred March shipments and exports still grew about 25 percent. But at 37.6x and a record high, with the street's own targets 3 to 9 percent away, the easy money is made. Hold; fresh entry on a pullback to Rs 1,880 to 1,910, the post-results base, or on evidence the 25 to 26 percent margin path arrives early. Levels: Rs 1,880 to 1,910 support; Rs 1,733 to 1,800 the pre-results shelf; Rs 2,001 the record to clear. Disclosure: Vijay Kumar Gupta, SEBI Registered Research Analyst, INH000020226, Vijay Gupta Advisory. SEBI registration and NISM certification do not guarantee performance or assure returns. Securities markets are subject to market risks. No holdings in the subject company.